about
Molecular profiling of cervical cancer progressionOther targeted drugs in melanomaClinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathwayModern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targetsPhenocopy--a strategy to qualify chemical compounds during hit-to-lead and/or lead optimizationEnhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injuryTargeting the transforming growth factor-beta signaling pathway in human cancer.Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sproutingId2, Id3 and Id4 overcome a Smad7-mediated block in tumorigenesis, generating TGF-β-independent melanoma.An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancerTargeting Nodal in malignant melanoma cells.Tissue stretch decreases soluble TGF-beta1 and type-1 procollagen in mouse subcutaneous connective tissue: evidence from ex vivo and in vivo models.Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell lineChemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers.A local paracrine and endocrine network involving TGFβ, Cox-2, ROS, and estrogen receptor β influences reactive stromal cell regulation of prostate cancer cell motility.Antisense-based cancer therapeutics: are we there yet?The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer MetastasisGalunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.In vitro models of pancreatic cancer for translational oncology research.Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now.A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.Desmoplasia in pancreatic cancer. Can we fight it?Cancer gene therapy: the power of negative thinking.Induction of heart valve lesions by small-molecule ALK5 inhibitors.Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.TGF-β signalling-related markers in cancer patients with bone metastasis
P2860
Q24653706-FB181DCB-2B32-4310-8A6C-5C1774038CE3Q26775594-4B7CC932-B4B8-403A-AE65-A0CD7F3F1343Q26797238-2FDEBD66-DE1D-4365-B5B4-248ED86BA834Q28303698-ACD2F3B9-1BDF-4C17-9C4E-147F970BCBB4Q28476479-7021ADA8-F319-4366-85CE-91BDC1755858Q28486225-49291A6E-7BA3-45AB-B099-2F985AA34427Q33517772-F66B6B97-4594-476F-B51B-D909238651CBQ33605773-6871556E-A540-421F-8DE7-FC4200C4ED97Q33652300-BED614ED-0C96-4B9D-AFC3-038F75A73D2AQ34345765-380D785D-F598-4892-8DB4-03DA489BB5FEQ34610503-FAED37D6-C1BE-4697-BC21-462A97CD6059Q34729690-4AF3F395-2A5C-493E-A832-F40013ECB372Q35024363-A4A272F8-EA94-41FD-8C17-7A62ED6B7558Q35490960-A42207EB-DBB7-4B48-8094-BBDEACF8C3F8Q35970073-443E0F2B-E50B-4B98-8150-EC38F7F8B6CBQ36458427-A02EE9E4-0031-4FCE-9848-0A5C22006560Q36985643-047C24CB-715B-4AAA-941B-21870A5D6BDAQ37183387-A0A963E3-6A35-4733-9BBA-1E6C886E66B3Q37384842-0C40C3A7-CECF-4377-8412-6B93A10B5139Q38056849-20160B61-72DE-4614-88F3-1DF5CCC0807DQ38379618-9A59FF03-B60B-4DB9-9BF5-C2C0FBA380F2Q38400938-FD7EA398-9340-4BBF-8E3F-02FD8FE7F36AQ41597479-847EA011-FDF3-46C5-8DB2-8B1EE55D0552Q45865376-F54E1CC2-0BE3-495A-90AE-985C3BE8B438Q51423313-811EE905-D225-4B45-8011-F5F5CBD45FA7Q55068795-038B2820-4D51-49F3-83C2-0FBB15169D22Q58614844-C77F9A1B-7C08-43DC-87B6-4764CE8BAC20
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
TGF-beta inhibitors for the treatment of cancer.
@ast
TGF-beta inhibitors for the treatment of cancer.
@en
type
label
TGF-beta inhibitors for the treatment of cancer.
@ast
TGF-beta inhibitors for the treatment of cancer.
@en
prefLabel
TGF-beta inhibitors for the treatment of cancer.
@ast
TGF-beta inhibitors for the treatment of cancer.
@en
P2093
P2860
P1476
TGF-beta inhibitors for the treatment of cancer.
@en
P2093
Brandi S Berry
Michael Lahn
Susanne Kloeker
P2860
P304
P356
10.1517/13543784.14.6.629
P407
P577
2005-06-01T00:00:00Z